PulseAugur
EN
LIVE 12:11:13
中文(ZH) 诺诚健华：奥布替尼治疗ITP新药上市申请获受理

Innocare Pharma's ITP drug application accepted by China regulators

By PulseAugur Editorial · [1 sources] ·

A new drug, 奥布替尼 (Obutini), developed by Innocare Pharma, has had its new drug application accepted by China's National Medical Products Administration for treating primary immune thrombocytopenia (ITP). This marks the first autoimmune disease indication for 奥布替尼 and addresses a current gap in the market, as no BTK inhibitors are approved for ITP in China. The company anticipates no immediate significant impact on its current financial performance from this development. AI

RANK_REASON Drug application acceptance for a specific condition. [lever_c_demoted from research: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Innocare Pharma's ITP drug application accepted by China regulators

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Drug application acceptance for a specific condition. [lever_c_demoted from research: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, policy
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
109 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    CStone Pharmaceuticals: Orelabrutinib New Drug Marketing Application for ITP Treatment Accepted

    36氪获悉，诺诚健华公告，公司自主研发的BTK抑制剂奥布替尼用于治疗原发免疫性血小板减少症(ITP)的新药上市申请(NDA)已获国家药监局受理。这是奥布替尼首个自身免疫性疾病适应症上市申请获受理，目前中国尚无BTK抑制剂获批治疗ITP。该事项不会对公司当前业绩产生重大影响。

RELATED ENTITIES

RELATED TOPICS